BDTX
Black Diamond Therapeutics, Inc. · Healthcare · Market cap $119.5M
Black Diamond Therapeutics, Inc. (BDTX) has 8 SEC Form 4 filings (8 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Sep 21, 2026.
- Industry:Biotechnology
- CEO:Mark A. Velleca
- Employees:21
- HQ:Cambridge, MA, US
- IPO:2020-01-31
No open-market insider trades for BDTX (Black Diamond Therapeutics, Inc.) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.
Frequently asked questions
How many SEC Form 4 insider filings does BDTX have?
Black Diamond Therapeutics, Inc. (BDTX) has 8 SEC Form 4 filings (8 transaction rows) in the rolling 365-day window, disclosed by 0 distinct insiders. Most recent filing: Sep 21, 2026.
When was the most recent SEC Form 4 filing for BDTX?
The most recent Form 4 filing for BDTX on Tracefour is dated Sep 21, 2026.
Can I get alerts for BDTX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Black Diamond Therapeutics, Inc. (BDTX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Black Diamond Therapeutics, Inc. is in the Healthcare sector.